Cellular distribution of insulin-like growth factor-II/mannose-6-phosphate receptor in normal human brain and its alteration in Alzheimer's disease pathology.
The insulin-like growth factor-II/mannose-6-phosphate (IGF-II/M6P) receptor is a multifunctional membrane glycoprotein, which binds different classes of ligands including IGF-II and M6P-bearing lysosomal enzymes. Besides participating in the process of endocytosis this receptor functions in the trafficking of lysosomal enzymes from the trans-Glogi network (TGN) or the cell surface to lysosomes. In Alzheimer's disease (AD) brain, marked overexpression of certain lysosomal enzymes in vulnerable neuronal populations and their association to beta-amyloid (Abeta) containing neuritic plaques has been correlated to altered metabolic functions. In the present study, we measured the levels of IGF-II/M6P receptor and characterized its distribution profile in selected regions of AD and age-matched normal postmortem brains. Western blot analysis revealed no significant alteration in the levels of IGF-II/M6P receptor either in the hippocampus, frontal cortex or cerebellum between AD and age-matched control brains. However, a significant gene dose effect of apolipoprotein E (APOE) epsilon4 allele on IGF-II/M6P receptor levels was evident in the hippocampus of the AD brain. At the cellular level, immunoreactive IGF-II/M6P receptors were localized in the neurons of the frontal cortex, hippocampus and cerebellum of control brains. In AD brains, the labeling of the neurons was less intense in the frontal cortex and hippocampus than in the age-matched control brains. Additionally, IGF-II/M6P receptor immunoreactivity was observed in association with a subpopulation of Abeta-containing neuritic plaques as well as tau-positive neurofibrillary tangles both in the frontal cortex and the hippocampus. Reactive glial cells localized adjacent to the plaques also occasionally exhibited IGF-II/M6P receptor immunoreactivity. These results, when analyzed in context of the established role of the IGF-II/M6P receptor in the regulation of the intracellular trafficking of lysosomal enzymes, suggest that alterations in IGF-II/M6P receptor levels/distribution are possibly associated with altered functioning of the lysosomal enzymes and/or loss of neurons observed in AD brains, especially in patients carrying APOE epsilon4 alleles.
Kar
S
S
Centre for Alzheimer and Neurodegenerative Research, Department of Medicine, University of Alberta, Edmonton, Alta., Canada T6G 2B7. skar@ualberta.ca
Poirier
J
J
Guevara
J
J
Dea
D
D
Hawkes
C
C
Robitaille
Y
Y
Quirion
R
R
D000368:Aged; D000544:Alzheimer Disease / Q000378:metabolism / Q000473:pathology*; D053327:Apolipoprotein E4; D001057:Apolipoproteins E / Q000378:metabolism; D015153:Blotting, Western / Q000379:methods; D001921:Brain / Q000378:metabolism* / Q000473:pathology*; D016022:Case-Control Studies; D005260:Female; D006801:Humans; D007150:Immunohistochemistry / Q000379:methods; D007335:Insulin-Like Growth Factor II / Q000378:metabolism*; D008297:Male; D011180:Postmortem Changes; D017527:Receptor, IGF Type 2 / Q000378:metabolism*
D053327:Apolipoprotein E4; D001057:Apolipoproteins E; D017527:Receptor, IGF Type 2; D007335:Insulin-Like Growth Factor II